(Total Views: 556)
Posted On: 12/14/2021 11:20:02 AM
Post# of 153930
unfortunately i can't listen to the call. I really hope someone asks the very basic question:
During 2021, your common shareholders sustained a loss of over 80% on their investment, despite numerous new trials and seemingly positive news on the science for Leronlimab.
What is the plan in 2022 to restore value to common shareholders?
During 2021, your common shareholders sustained a loss of over 80% on their investment, despite numerous new trials and seemingly positive news on the science for Leronlimab.
What is the plan in 2022 to restore value to common shareholders?
(2)
(1)
